American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practicing hematologists improve the quality
of care provided to patients

Drug Resources

Newly approved therapies and access information on hematologic drugs

Consult a Colleague

Service that provides advice on clinical questions in one to two days

Professional Development

Services to support hematologists with continuing medical education and recertification

Policy Resources

Information on federal programs and policies affecting clinical practice

ASH Practice Update

Email newsletter highlighting the Society's latest educational offerings and developments impacting clinicians

View all Ask the Hematologist
  • FDA Approves Idelalisib for Relapsed Chronic Lymphocytic Leukemia

    On July 23, 2014, the U.S. Food and Drug Administration (FDA) approved idelalisib (Zydelig® tablets, Gilead Sciences, Inc.) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.

  • FDA Approves an Oral Suspension of mercaptopurine

    On April 28, 2014, the U. S. Food and Drug Administration approved an oral suspension of mercaptopurine (Purixan ®, NOVA Laboratories Limited). Mercaptopurine is a 20 mg/ml oral suspension. Purixan is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen.

  • FDA Approves ofatumumab for Chronic Lymphocytic Leukemia

    On April 17, 2014, the U. S. Food and Drug Administration approved ofatumumab (Arzerra Injection, for intravenous infusion; GlaxoSmithKline) in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

  • FDA Approves Ibrutinib to Treat Chronic Lymphocytic Leukemia

    FDA Approves Ibrutinib to Treat Chronic Lymphocytic Leukemia In collaboration with the Food and Drug Administration (FDA), and as a service to our members, ASH provides information about newly approved therapies and other important FDA actions (e.g., updated safety information, ne

View all FDA alerts
View all policy news
back to top